GO TEST FINALE
We are researching the best treatment strategy for gout patients in remission and who use urate-lowering therapy (allopurinol, benzbromarone or febuxostat). A continued urate-lowering therapy is compared to a taper to stop strategy, with the possibility of restarting the medication in case of recurrent flaring.
Study
It concerns a randomized clinical trial in which patients are randomized into one of the two treatment groups:
- In one group urate-lowering therapy is continued with a treatment target of serum urate ≤0.36mmol/l
- In one group urate-lowering therapy is tapered to stop, and in case of recurrent flaring a restart of urate-lowering therapy is possible.
It concerns a multicenter study and is executed in 9 different centres: Sint Maartenskliniek, Bravis ziekenhuis, Bernhoven ziekenhuis, Medisch Spectrum Twente, Erasmus MC, Maastricht UMC, Martini ziekenhuis, Zorggroep Twente en VieCuri Medisch centrum.
Participants
In total, 310 patients are included who meet the following criteria:
- They are free of gout flares and tophi for at least 12 months
- They use either allopurinol, benzbromaron or febuxostat
- They do not use anti-inflammatory medication such as colchicine, glucocorticoids or NSAIDs to prevent gout flares.
The study started February 2021, the first results are expected in the fall of 2025.
